Dec. 2 - A quest to stop heart attacks, gene therapy for dementia and Bluebird gets speedy FDA review

A startup led by Novartis veteran raises $80M to develop gene therapies for the brain; Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy; GSK dives into NASH, RNA interference with Arrowhead deal View online | Signup | Forward

Gene Therapy weekly Dec.​ 2,​ 2021 | This week's gene therapy news and insights for biopharma leaders   BROUGHT TO YOU BY — Bio-Rad Vericheck ddPCR Mycoplasma Solution Ensure consistent quality during the development and manufacturing of biopharma therapies with Bio-Rad's Droplet Digital PCR (ddPCR). Learn how the absolute quantification of ddPCR precisely measures contamination. Learn more.   Deep Dive Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them. After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, Verve Therapeutics, that seeks to prevent them. A startup led by Novartis veteran raises $80M to develop gene therapies for the brain AviadoBio, which was built around research from the lab of Christopher Shaw at King's College London, is backed by venture firms NEA and Monograph Capital. Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy The regulator will decide whether to approve Bluebird's treatment by next May, but its evaluation is beginning more than a year later than the biotech hoped. Sponsored Content by Biopharma Dive's studioID What pharma often overlooks in their data strategy Aggregation is key to derive insights from pharma data, but many times an ineffective contract keeps those insights out of reach. Learn how to aggregate data to track key KPIs and gain commercial launch insights in this webinar. GSK dives into NASH, RNA interference with Arrowhead deal GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people that has proven to be a tough target for drugmakers.  Read more news Featured Resources FROM: Catalent Drive Innovation in Cell & Gene Therapy Production [Webinar] - Accelerating Advances in Cell and Gene Therapy Production [Press Release] - Catalent's Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus in Harmans, Maryland, Increases to $360M [Podcast] - Manufacturing Cell Therapies with an Individualized Mindset What We're Reading The New York Times A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. Endpoints News Another epigenome editing startup launches from a pair of the field’s longtime leaders Spectrum One-shot gene therapy for Angelman syndrome shows promise in mice FierceBiotech Astellas becomes latest Dyno gene therapy partner with $1.6B biobucks pact to join Roche, Novartis, Sarepta Suggest a story we should read Upcoming Events Biosimilars and Real-World Evidence: A Path to Regulatory Efficiency and Adoption Dec. 9, 2021 - Dec. 9, 2021 | Webinar 2 pm ET Getting Your Data Aggregation Contract Right in Pharma Dec. 2, 2021 - Dec. 2, 2021 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Gene Therapy Weekly with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Gene Therapy Weekly. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Gene Therapy Weekly is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip